EmphyCorp. Inc.

**Treatment** 

**Idiopathic Pulmonary Fibrosis** 

(ILD Orphan Drug Designation)

No Adverse Events Reported

**Pulmonary Fibrosis & IPF** 

(ILD Orphan Drug Designation)

No Adverse Events Reported

**Cystic Fibrosis** 

(ILD Orphan Drug Designation)

**Long COVID Treatment** 

(No Adverse Events Reported)

Influenza Treatment & Preventative

(No Adverse Effects)

Unmet Needs - Congestion, Allergic

Rhinitis, COPD, Asthma for Diabetic,

Hypertensive, Pregnant - No Steroids

**COPD** and Asthma - All Ages

No Adverse Effects

**Severe COPD Treatment** 

(Also Lowered High Blood Pressure)

**High Blood Pressure and Pulmonary** 

**Hypertension Treatment** 

**COVID-19 Treatment** 

(No Adverse Effects)

Racehorses - Increase SaO2

Alzheimer's

**Concussions** 

**Cancer Pre-Treatment** 

**OTC Nasal Spray sold US & China** 

To Date: (24) Sets of Human Clinical

Trials completed. (6) Peer Reviews.

## EmphyCorp N115 Rx Nasal and Oral Spray Drug Pipeline w/ No Side Effects 1/3/2025

Drug

N115 Non-Steroidal

**Nasal Spray** 

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

**Nasal Spray** 

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

**Nasal Spray** 

N115 Non-Steroidal

Nasal Spray w/ no

adverse effects

N115 Non-Steroidal

Nasal & Oral Spray

N115 Non-Steroidal

Nasal & Oral Spray

N115 Non-Steroidal

Nasal & Oral Spray

N115 Non-Steroidal

Nasal Spray

N115 Nasal Spray

and Oral Spray

8 Drug Patents (3 New: Hypoxemia & Dyspnea & Coughing, Apoptosis of Myofibroblasts, Coronavirus/Flu) (x = completed)

Phase 2

Χ

Χ

Orphan Drug

NDA

Χ

Χ

Χ

Χ

Χ

Χ

Χ

Pilot Study

Pilot Study

Pilot Study

(1) US and (3) Chinese Approved Nasal Sprays

and lung diseases & slowing/stopping Lung Fibrosis

(3) New Drug Patents for the treatment of all sinus

Phase 1

Χ

Χ

Χ

Χ

Χ

Χ

Χ

Χ

Pilot Study

Plan

Χ

Pilot Study

Χ

Χ

Χ

Phase 3

X - Pivotal

Phase III for

**NDA** 

**Protocol** 

Ready

Χ

**Protocol** 

Ready

Protocol

Ready

Protocol

Readv

Protocol

Ready

Χ

**NDA** 

Χ

**Note** 73% Reduction in Coughing &

Improved Lung Function

(Hypoxemia, Dyspnea)

Met (8) Medical Endpoints.

Clinically & Statistically

Significant Results

FEV1, Coughing, Hypoxemia, Dyspnea, and Sleeping Better

Expanded Phase III in 2025. Met (8) Medical Endpoints

Increases Nasal Nasal Nitric Oxide to kill Viruses/Shut IL-6

Safe Non-Steroidal

for 30 to 60 Million People

in US Alone

FEV1, Coughing, Hypoxemia,

Dyspnea

Also reduced High Blood

Pressure to Normal Levels

Discovered in Phase II Severe

**COPD Patient Clinicals** 

Increases Nasal Nitric Oxide

to kill Viruses/Shut IL-6

Stops Nasal Bleeding

3 Million Patients Treated

(8) Drug Patents